Contagion® will be heading to Seattle, Washington, Monday, March 4, 2019, to report on the annual Conference on Retroviruses and Opportunistic Infections (CROI), a forum that brings together researchers from around the world to discuss the latest research to help in the battle against HIV/AIDS and other related infectious diseases.
As a trusted source in the realm of HIV, the editorial team of Contagion® strives to consistently report on new developments made in the fight against the virus. Some of our recent coverage includes a feature on U=U, the president’s initiative to end the HIV epidemic by 2030, the potential to fight HIV via gene editing, and home-based pre-exposure prophylaxis (PrEP) monitoring.
What’s on the docket for the conference this year?
Coverage will be focused on the safety of antiretroviral therapy (ART) in pregnancy; use of daily emtricitabine and tenofovir alafenamide (F/TAF) and emtricitabine and tenofovir disoproxil fumarate (F/TDF) for HIV PrEP; long-acting injectable agents in the pipeline; U=U and TasP; weight gain and/or metabolic changes during ART; and, of course, the latest news on a cure.
Additional coverage will focus on increasing PrEP adherence, access, and retention of care. Contagion® will also be reporting the latest data from clinical studies of novel agents and the latest news in drug delivery systems.
In keeping with our dedication to providing our readership with the most timely and relevant content to support their practices and improve patient outcomes, Contagion® editors will provide exclusive written coverage, along with engaging video interviews with several key opinion leaders on important issues and advancements made in the realm of infectious disease.
Some of the presentations that we will cover in the upcoming week include one from Julia Marcus, PhD, MPH, from Harvard Pilgrim Health Care Institute, discussing her research on the use of electronic health records to identify PrEP candidates; and from Monica Ghandi, MD, MPH, of University of California San Francisco, who will provide insight on ART options for women of reproductive potential. We will also speak with Pietro L. Vernazza, MD, of Kantonsspital in Switzerland, on the scientific underpinnings of U=U; and Kavita Misra, PhD, MPH, of the NYC Health Department, who will detail a study focusing on the impact of PrEP on drug resistance in New York City. Jean-Michel Molina, MD, PhD, with University of Paris Diderot, will discuss PrEP failures and resistance; and Karin Bosch, PhD, of the US Centers for Disease Control and Prevention, will speak about trends of opioid overdose deaths in individuals with HIV infections.
Going to the conference? Be sure to say hello between interviews or sessions; we’ll be there!
Not going to the conference? Be sure to sign up for our Conference updates.